The belly-appearance questionnaire, what it asked, and why regulators weighed it differently

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
The phase 3 trials included patient-reported outcomes as secondary endpoints: a belly-appearance distress score, in which participants rated how troubled they were by the size and appearance of their abdomen, and broader body-image and quality-of-life instruments. Distress scores improved more in the tesamorelin groups than with placebo at 26 weeks, in parallel with the fall in visceral fat, and the improvement reversed in those switched to placebo. The United States regulator cited the patient-reported improvement as supporting clinical meaningfulness; the European committee regarded the questionnaire evidence as insufficient to establish benefit in a condition that was not life-threatening.

What was asked

The distress instrument asked participants to rate their concern about abdominal appearance on a scale; body-image instruments asked about satisfaction with specific body regions; quality-of-life instruments covered general health and function. The belly-appearance measure was developed for the lipodystrophy population and validated before the trials. Changes were modest in absolute terms and statistically significant against placebo.

Patient-reported measures are by design subjective and are harder to blind than an imaging endpoint, which both regulators noted.

How the two regulators read it

For the United States review, a reduction in a disfiguring fat depot accompanied by less distress about it was a meaningful benefit for an identified population. For the European review, the absence of an effect on any clinical outcome left a surrogate endpoint supported by a questionnaire, and the committee judged that insufficient. The same data, read against different standards for what counts as benefit.

The divergence is described from the regulatory side on the page about the European application.

Why it is here

Because the patient-reported findings are part of the evidence and the disagreement about their weight is instructive. It describes trial endpoints and no use of the pack.

Tesamorelin is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Tesamorelin Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

What was asked?

The distress instrument asked participants to rate their concern about abdominal appearance on a scale; body-image instruments asked about satisfaction with specific body regions; quality-of-life instruments covered general health and function. The belly-appearance measure was developed for the lipodystrophy population and validated before the trials. Changes were modest in absolute terms and statistically significant against placebo.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Tesamorelin Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.